Assembly Biosciences (NASDAQ:ASMB) Downgraded to Sell at StockNews.com

StockNews.com downgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a sell rating in a report released on Thursday morning.

Assembly Biosciences Price Performance

ASMB stock opened at $13.30 on Thursday. The company’s 50-day moving average is $12.10 and its 200-day moving average is $10.58. Assembly Biosciences has a 1 year low of $7.69 and a 1 year high of $20.04.

Insider Transactions at Assembly Biosciences

In related news, major shareholder Alexander Schornstein acquired 24,999 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were bought at an average price of $9.36 per share, with a total value of $233,990.64. Following the transaction, the insider now directly owns 655,357 shares of the company’s stock, valued at $6,134,141.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors have recently added to or reduced their stakes in ASMB. Vanguard Group Inc. grew its stake in shares of Assembly Biosciences by 4.4% during the 4th quarter. Vanguard Group Inc. now owns 2,339,088 shares of the biopharmaceutical company’s stock worth $1,918,000 after acquiring an additional 99,092 shares during the period. Millennium Management LLC increased its stake in shares of Assembly Biosciences by 3.9% in the second quarter. Millennium Management LLC now owns 1,418,180 shares of the biopharmaceutical company’s stock worth $2,978,000 after purchasing an additional 53,157 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Assembly Biosciences by 52.1% in the first quarter. Renaissance Technologies LLC now owns 765,800 shares of the biopharmaceutical company’s stock valued at $644,000 after purchasing an additional 262,416 shares during the period. Geode Capital Management LLC lifted its stake in shares of Assembly Biosciences by 12.2% during the 2nd quarter. Geode Capital Management LLC now owns 507,649 shares of the biopharmaceutical company’s stock valued at $584,000 after buying an additional 55,021 shares in the last quarter. Finally, Acuitas Investments LLC bought a new position in Assembly Biosciences in the 4th quarter worth approximately $218,000. 19.92% of the stock is owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.